More than 40% of women have dense breast tissue. Here’s why mammography falls short—and how dense breast imaging is reshaping ...
Oncology Imaging AI Strategy Pulse 2025-2032: Pathways, Platforms & Playbooks is a global deep-dive on how cancer imaging AI is actually being bought, deployed, and scaled across health systems, OEMs, ...
Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.
Cancer imaging is entering a phase where malignant cells no longer hide in murky grayscale but flare into view with surgical precision. Across operating rooms, scanners, and even blood tests, ...
Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
In a prospective imaging study of 200 adults with lung cancer, photon-counting CT reduced radiation exposure, yielded fewer ...
The oncology imaging AI market is poised for significant expansion through 2032, with key opportunities in measurement-first ...
A Chicago doctor is using new FDA-approved technology that makes cancer cells glow during surgery. Here's how it works.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...
The stakes are real. In 2026, an estimated 42,670 people will die from breast cancer nationwide, including nearly 3,400 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results